Znn3bq.jpeg
ÉÇÍ·´óѧº£Ñó¿ÆÑ§½ÓÊܵ÷¼Á
²é¿´: 619  |  »Ø¸´: 2
¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û1´Î£¬×÷Õßraoqun20Ôö¼Ó½ð±Ò 1 ¸ö
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£

raoqun20

ľ³æ (ÖªÃû×÷¼Ò)


[×ÊÔ´] »ùÒòÓ¢Óïרҵ´Ê»ã

A
ÏÙÜÕÍѰ±Ã¸È±·¦Ö¢ adenosine deaminase deficiency (ADA)
ÏÙ²¡¶¾ adenovirus
Alagille×ÛºÏÕ÷ Alagille syndrome
µÈλ»ùÒò allele
°±»ùËá amino acids
¶¯ÎïÄ£ÐÍ animal model
¿¹Ìå antibody
µòÍö apoptosis
·-°Í×ÛºÏÕ÷ ataxia-telangiectasia
³£È¾É«ÌåÏÔÐÔ autosomal dominant
³£È¾É«Ìå autosome
B
ϸ¾úÈ˹¤È¾É«Ìå bacterial artificial chromosome (BAC)
¼î»ù¶Ô base pair
ÏÈÌìȱÏÝ birth defect
¹ÇËèÒÆÖ² bone marrow transplantation
BRCA1/BRCA2
C
°© cancer
ºóÑ¡»ùÒò candidate gene
°© carcinoma
cDNAÎÄ¿â cDNA library
ϸ°û cell
ȾɫÌå chromosome
¿Ë¡ cloning
ÃÜÂë codon
ÌìÉúµÄ congenital
ÖØµþȺ contig
ÄÒÐÔÏËά»¯ cystic fibrosis
ϸ°ûÒÅ´«Í¼ cytogenetic map
D
ȱʧ deletion
ÍÑÑõºËÌǺËËá deoxyribonucleic acid (DNA)
ÌÇÄò²¡ diabetes mellitus
¶þ±¶Ìå diploid
DNA¸´ÖÆ DNA replication
DNA²âÐò DNA sequencing
ÏÔÐ﵀ dominant
Ë«ÂÝÐý double helix
¸´ÖÆ duplication
E
µçÓ¾ electrophoresis
Ellis - van Creveld syndrome
ø enzyme
ÍâÏÔ×Ó exon
F
¼Ò×åÐÔµØÖк£ÈÈ familial Mediterranean fever
Ó«¹âԭλÔÓ½» fluorescence in situ hybridization (FISH)
´àÐÔXȾɫÌå×ÛºÏÕ÷ Fragile X syndrome
G
»ùÒò gene
»ùÒòÀ©Ôö gene amplification
»ùÒò±í´ï gene expression
»ùÒòͼÆ× gene mapping
»ùÒò¿â gene pool
»ùÒòÖÎÁÆ gene therapy
»ùÒò×ªÒÆ gene transfer
ÒÅ´«ÃÜÂë genetic code (ATGC)
ÒÅ´«×Éѯ genetic counseling
ÒÅ´«Í¼ genetic map
ÒÅ´«±ê¼Ç genetic marker
ÒÅ´«²¡É¸²é genetic screening
»ùÒò×é genome
»ùÒòÐÍ genotype
ÖÖϵ germ line
H
µ¥±¶Ìå haploid
haploinsufficiency
ÔìѪ¸Éϸ°û hematopoietic stem cell
ѪÓѲ¡ hemophilia
ÔÓºÏ×Ó heterozygous
¸ß¶È±£ÊØÐòÁÐ highly conserved sequence
Hirschsprung²¡ Hirschsprung's disease
´¿ºÏ×Ó homozygous
È˹¤È¾É«Ìå human artificial chromosome (HAC)
ÈËÀà»ùÒò×鼯»® Human Genome Project
ÈËÀàÃâÒßȱÏݲ¡¶¾ human immunodeficiency virus (HIV)/
»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷ acquired immunodeficiency syndrome (AIDS)
huntingtonÎ赸²¡ Huntington's disease
ÔÓ½» hybridization
I
ÃâÒßÖÎÁÆ immunotherapy
ԭλÔÓ½» in situ hybridization
¼Ì³ÐµÄ inherited
²åÈë insertion
֪ʶ²úȨ intellectual property rights
K
Çóý knockout
L
°×Ѫ²¡ leukemia
¿â library
¼ü¡¢Á¬½Ó linkage
²¿Î»¡¢³¡Ëù locus
ÓÅÊÆ¶ÔÊýÆÀ·Ö LOD score
ÁܰÍϸ°û lymphocyte
M
»ûÐÎ malformation
Ãèͼ mapping
񈬀 marker
ºÚÉ«ËØÁö melanoma
Ãϵ¶û Mendel, Johann (Gregor)
Ãϵ¶ûÒÅ´« Mendelian inheritance
ÐÅʹRNA messenger RNA (mRNA)
[·ÖÁÑ]ÖÐÆÚ metaphase
΢Õó¼¼Êõ microarray technology
ÏßÁ¢ÌåDNA mitochondrial DNA
µ¥ÌåÐÔ monosomy
СÊóÄ£ÐÍ mouse model
¶à·¢ÐÔÄÚ·ÖÃÚÁö²¡ multiple endocrine neoplasia, type 1 (MEN1)
Í»±ä mutation
N
Éñ¾­ÏËάÁö²¡ neurofibromatosis
ÄáÂü-Ƥ¿Ë²¡ Niemann-Pick disease, type C (NPC)
non-directiveness
RNAÓ¡¼Ç Northern blot
ºËÜÕËá nucleotide
Éñ¾­ºË nucleus
O
¹ÑºËÜÕËá oligo
°©»ùÒò oncogene
P
p53
Parkinson²¡ Parkinson's disease
רÀûȨ patent
Ѫϵ/Æ×ϵ pedigree
±íÐÍ phenotype
ÎïÀíͼÆ× physical map
¶àÖ¸»ûÐÎ/¶àÖº»ûÐÎ polydactyly
¾ÛºÏøÁ´·´Ó¦ polymerase chain reaction (PCR)
¶à̬ÐÔ polymorphism
¶¨Î»¿Ë¡ positional cloning
Ô­·¢ÐÔÃâÒßȱÏÝ primary immunodeficiency
ÒýÎï primer
Ô­ºË pronucleus
ǰÁÐÏÙ°© prostate cancer
µ°°× protein
R
ÒþÐÔ recessive
Äæ×ªÂ¼²¡¶¾ retrovirus
ºËÌǺËËá ribonucleic acid (RNA)
ºËÌÇÌå ribosome
risk communication
S
ÐòÁбê¼Çλµã sequence-tagged site (STS)
ÁªºÏÃâÒßȱÏÝ severe combined immunodeficiency (SCID)
ÐÔȾɫÌå sex chromosome
°éÐ﵀ sex-linked
Ìåϸ°û somatic cells
DNAÓ¡¼Ç Southern blot
¹âÆ×ºËÐÍ spectral karyotype (SKY)
Ìæ´ú substitution
×Ôɱ»ùÒò suicide gene
×ÛºÏÕ÷ syndrome
T
¼¼ÊõתÈà technology transfer
ת»ùÒòµÄ transgenic
Ò×λ translocation
ÈýÌåÐÍ trisomy
Ö×ÁöÒÖÖÆ»ùÒò tumor suppressor gene
V
ÔØÌå vector
W
µ°°×ÖÊÓ¡¼Ç Western blot
Wolfram×ÛºÏÕ÷ Wolfram syndrome
Y
½ÍĸÈ˹¤È¾É«Ìå yeast artificial chromosome (YAC)
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

½­Á÷¶ù

ľ³æ (ÕýʽдÊÖ)


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

¶àл¥Ö÷Ãâ·Ñ·ÖÏí£¡£¡£¡
2Â¥2007-05-17 21:47:24
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ÉòѦÄþ

Òø³æ (СÓÐÃûÆø)


ÉϵÄÊ»¯Ñ§£¬ÏÖÔÚÒª²¹ÉúÎïÁË
3Â¥2007-05-20 01:24:52
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ raoqun20 µÄÖ÷Ìâ¸üÐÂ
¡î ÎÞÐǼ¶ ¡ï Ò»ÐǼ¶ ¡ï¡ï¡ï ÈýÐǼ¶ ¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 274Çóµ÷¼Á +12 ɽ°¢Âû 2026-04-07 12/600 2026-04-14 16:46 by zhouxiaoyu
[¿¼ÑÐ] ²ÄÁÏרҵ344Çóµ÷¼Á +17 hualkop 2026-04-10 22/1100 2026-04-14 16:21 by sxdj2
[¿¼ÑÐ] 0854µ÷¼Á +11 ³¤¹­°Á 2026-04-12 14/700 2026-04-14 16:07 by ÄæË®³Ë·ç
[¿¼ÑÐ] ũѧ0904 312Çóµ÷¼Á +4 Say Never 2026-04-11 4/200 2026-04-14 09:10 by zs92450
[¿¼ÑÐ] 310Çóµ÷¼Á +15 666ÕæºÃ 2026-04-11 17/850 2026-04-13 22:27 by pies112
[¿¼ÑÐ] Ò»Ö¾Ô¸2110£¬»¯Ñ§Ñ§Ë¶310·Ö£¬±¾¿ÆÖصãË«·ÇÇóµ÷¼Á +20 ŬÁ¦·Ü¶·112 2026-04-08 20/1000 2026-04-13 14:24 by ÕÅzhihao
[¿¼ÑÐ] һ־Ը˫·Ç085400µç×ÓÐÅÏ¢344 Çóµ÷¼Á£¬¶Ô²ÄÁϺͻ¯Ñ§·½ÏòÒ²¸ÐÐËȤ +12 ÎÞÇéµÄСÑò 2026-04-09 13/650 2026-04-13 14:17 by ÕÅzhihao
[¿¼ÑÐ] 339Çóµ÷¼Á +4 hanwudada 2026-04-12 4/200 2026-04-13 12:03 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 266µ÷¼Á +10 daya sun 2026-04-07 11/550 2026-04-13 10:12 by fenglj492
[¿¼ÑÐ] 314Çóµ÷¼Á +24 wakeluofu 2026-04-09 25/1250 2026-04-13 08:58 by lhj2009
[¿¼ÑÐ] 085410 273Çóµ÷¼Á +10 X1999 2026-04-09 10/500 2026-04-12 09:24 by ÄæË®³Ë·ç
[¿¼ÑÐ] 085404 293Çóµ÷¼Á +9 ÓÂÔ¶¿â°®314 2026-04-08 9/450 2026-04-12 02:24 by Çï¶¹²ËÑ¿
[¿¼ÑÐ] 352 Çóµ÷¼Á +6 yzion 2026-04-11 8/400 2026-04-11 16:24 by Ã÷Ô´ËʱÓÐ
[¿¼ÑÐ] 087100³õÊÔ311Çóµ÷¼Á +4 ÈÎÑÅÇÙ 2026-04-09 4/200 2026-04-11 10:33 by zhq0425
[¿¼ÑÐ] 337Çóµ÷¼Á +4 ÑÐs. 2026-04-10 4/200 2026-04-11 08:57 by zhq0425
[¿¼ÑÐ] ÉúÎïѧ308Çóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£© +6 ÏàÐűػá¹ââÍòÕ 2026-04-10 6/300 2026-04-11 05:23 by zhuwenxu
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖÐÄÏ´óѧÎïÀíѧ£¬Ó¢Ò»66£¬Çóµ÷¼Á +4 ³¤ÑÌì½ì» 2026-04-08 5/250 2026-04-10 10:31 by Ó±¹û¶ù
[¿¼ÑÐ] 085501»úеӢ¶þ77×Ü·Ö294Çóµ÷¼Á£¬½ÓÊÜ¿çרҵѧϰ +6 ÊØ·¨¹«ÃñØÁ¼Í 2026-04-08 6/300 2026-04-09 15:55 by wp06
[¿¼ÑÐ] 0860004 Çóµ÷¼Á 309·Ö +6 Yin DY 2026-04-09 6/300 2026-04-09 10:19 by °¡Àî999
[¿¼ÑÐ] 316Çóµ÷¼Á +4 15318418673 2026-04-07 4/200 2026-04-07 22:12 by hemengdong
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û